Navigation Links
Feinstein Institute researcher publishes new perspective on sepsis
Date:4/17/2014

MANHASSET, NY In a review published in the April issue of Immunity, Kevin J. Tracey, MD, president of The Feinstein Institute for Medical Research, says it's time to take a fresh look at the medical community's approach to treating sepsis, which kills millions worldwide every year, including more than 200,000 Americans.

Sepsis occurs when molecules released into the bloodstream to fight an injury or infection trigger inflammation throughout the body. Inflammation is necessary for maintaining good health without inflammation, wounds and infections would never be controlled or heal. However, persistent and constant inflammation often results in organ dysfunction or damage, leading to death 28 to 50 percent of people who suffer from sepsis die from the condition. In addition to the toll in human lives, sepsis costs healthcare systems billions of dollars each year much of the costs attributed to expenses incurred during weeks or months-long stays in intensive care units.

The review, co-written by Dr. Tracey and Clifford S. Deutschman, professor of Anesthesiology and Critical Care at the University of Pennsylvania, notes that unlike other major epidemic illnesses, treatment for sepsis is nonspecific and limited primarily to support of organ function and administration of intravenous fluids, antibiotics and oxygen. There are no approved drugs that specifically target sepsis. They argue that to develop therapeutic options that treat sepsis, a new approach might be needed.

Sepsis, Drs. Tracey and Deutschman wrote, "is not a stereotypical, steadily progressive immunological process that follows infection or injury; that innate and adaptive immune responses do not inevitably damage host cells; and that the long-held notion that sepsis is a distinct immunological disorder is incorrect. Rather, understanding sepsis requires reframing the research focus to identify immunometabolic and neurophysiological mechanisms of cellular and organ dysfunction."

The review explains that severe sepsis and persistent critical illness (PCI), which result in organ dysfunction that lasts for weeks or months, are not immunopathologies as previously thought. Immunopathology is a branch of medicine that deals with immune responses associated with disease. It includes the study of the pathology of an organism, organ system, or disease with respect to the immune system, immunity, and immune responses. Much of the efforts to treat sepsis have been focused in this area. Although much has been learned about sepsis and PCI as a result, this approach has not led to any currently approved targeted treatment.

Recent discoveries indicate that severe sepsis and PCI are not caused by immune system dysfunction alone, but also by a failure of homeostasis a failure in the body to maintain stability of its internal environment in response to changes in external conditions. Now that researchers know this, it will be crucially important to study aspects of homeostasis, including the deregulation of metabolism, neural reflexes, energy utilization and cell stress. Greater understanding in these areas has potential for resulting in improved and effective treatment for severe sepsis and PCI.


'/>"/>

Contact: Emily Ng
eng3@nshs.edu
516-562-2670
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related medicine news :

1. Feinstein Institute Researcher Joins International Partnership in Neuroscience Research
2. Feinstein Institute researchers show a genetic overlap in schizophrenia and cognitive ability
3. Feinstein Researcher Receives 2013 Best of Manhasset Award
4. Feinstein Institute Encourages Science Education for NY Area Middle and High School Students
5. Feinstein Institute Researcher Organizes LI Alzheimer’s Consortium
6. Feinstein Institute to Receive $330,000 Grant to Support Research of Childhood Cancer
7. North Shore-LIJ Health System's Feinstein Institute to Receive $250,000 Grant from Lymphoma Research Foundation Grant to support research of Chronic Lymphocytic Leukemia
8. Summer Benefit Concert Raised More Than $1.5 Million for Feinstein Institute
9. Long Island Bike Challenge Rides to Raise Money for North Shore-LIJ's Feinstein Institute of Medical Research
10. Feinstein Institute, Hofstra North Shore-LIJ School of Medicine at 36th Annual Conference on Shock
11. North Shore-LIJ's Feinstein Institute Hosts Academic Commencement and Convocation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... MO (PRWEB) , ... April 29, 2016 , ... International ... Technology Seminar on May 3 and 4 at the Doubletree by Hilton Hotel in ... is dedicated to marketing and applications technologies for protein ingredients. , At the seminar, ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society for Assisted ... endocrinologists are required to report in vitro fertilization (IVF) delivery rates ... the practice of assisted reproductive technologies in the United States. , This ...
(Date:4/29/2016)... ... April 29, 2016 , ... Orthodontics Limited, ... founders, Dr. Gemmi and Dr. Middleberg, were asked by Invisalign to ... During the seminar, titled “Advancing the Biomechanics of Invisalign Clear Aligners,” Dr. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ProText Layouts is a set of 30 ... . With ProText Layouts, video editors can create an energetic typography video with ... scale of texts. Creating text-based videos have never been easier. , ProText Layouts ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... today the open availability of a new CDISC standard, Clinical Trial Registry ... clinical trials. This innovative standard will make it possible to build applications ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 TapImmune,Inc. ... innovative peptide and gene-based immunotherapeutics and vaccines for the treatment ... presenting at the 3rd Annual Growth Capital Expo ... , 2016 at Caesars Palace in Las Vegas, Nevada.  ... Wednesday, May 4 th by Dr. John N. ...
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... digital health technology platform, which specializes in live ... into scalable digital products, Zillion enables companies to ... empower consumers to take control of their health. ... video conferencing – including one-to-one, group and webcast ...
Breaking Medicine Technology: